These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31650721)

  • 1. What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
    Kim JW
    J Korean Med Sci; 2019 Oct; 34(41):e277. PubMed ID: 31650721
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals.
    Lee DH; Ryu SH; Myung HJ; Shin YJ; Lee SH; Park TY; Moon JS
    Korean J Gastroenterol; 2021 Feb; 77(2):88-91. PubMed ID: 33633000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
    Lee HW; Yoo KY; Won JW; Kim HJ
    Gut Liver; 2017 Sep; 11(5):721-727. PubMed ID: 28874040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    Suda G; Furusyo N; Toyoda H; Kawakami Y; Ikeda H; Suzuki M; Arataki K; Mori N; Tsuji K; Katamura Y; Takaguchi K; Ishikawa T; Tsuji K; Shimada N; Hiraoka A; Yamsaki S; Nakai M; Sho T; Morikawa K; Ogawa K; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kato K; Ueno Y; Iio E; Tanaka Y; Kurosaki M; Kumada T; Chayama K; Sakamoto N
    J Gastroenterol; 2018 Jan; 53(1):119-128. PubMed ID: 28560477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
    Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
    J Med Virol; 2019 Dec; 91(12):2158-2165. PubMed ID: 31452206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
    Yoneyama H; Morishita A; Iwama H; Fujita K; Masaki T; Tani J; Tadokoro T; Nomura T; Sakamoto T; Oura K; Takuma K; Nakahara M; Mimura S; Deguchi A; Oryu M; Tsutsui K; Himoto T; Shimotohno K; Wakita T; Kobara H; Masaki T
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1126-1135. PubMed ID: 32839985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
    Suzuki F; Hatanaka N; Bando E; Nakamura K; Komoto A
    Hepatol Int; 2018 May; 12(3):244-253. PubMed ID: 29900486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
    Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
    Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
    Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Inada Y; Uto H; Hiramine Y; Kure T; Fujisaki K; Hashiguchi M; Hori T; Oshige A; Imanaka D; Saishoji A; Taniyama O; Sakae H; Tamai T; Moriuchi A; Ido A
    J Gastroenterol; 2017 Jul; 52(7):855-867. PubMed ID: 28078469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
    Ikeda H; Watanabe T; Okuse C; Matsumoto N; Ishii T; Yamada N; Shigefuku R; Hattori N; Matsunaga K; Nakano H; Hiraishi T; Kobayashi M; Yasuda K; Yamamoto H; Yasuda H; Kurosaki M; Izumi N; Yotsuyanagi H; Suzuki M; Itoh F
    J Med Virol; 2017 Jan; 89(1):99-105. PubMed ID: 27329864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Hirooka Y; Goto H
    J Med Virol; 2018 Apr; 90(4):736-744. PubMed ID: 29111616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
    Kurokawa K; Ohki T; Kato J; Fukumura Y; Imai M; Shibata C; Arai J; Kondo M; Takagi K; Kojima K; Seki M; Mori M; Toda N; Tagawa K
    J Med Case Rep; 2020 May; 14(1):62. PubMed ID: 32456712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
    Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Jan; 89(1):91-98. PubMed ID: 27256744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil.
    Holzmann I; Tovo CV; Minmé R; Leal MP; Kliemann MP; Ubirajara C; Aquino AA; Araujo B; Almeida PRL
    Braz J Infect Dis; 2018; 22(4):317-322. PubMed ID: 30036490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
    Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
    Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
    Morio R; Imamura M; Kawakami Y; Morio K; Kobayashi T; Yokoyama S; Kimura Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Nelson Hayes C; Aikata H; Takahashi S; Miki D; Ochi H; Mori N; Takaki S; Tsuji K; Chayama K
    J Gastroenterol; 2017 Apr; 52(4):504-511. PubMed ID: 27631593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    Morishita N; Sakamori R; Yamada T; Kai Y; Tahata Y; Urabe A; Yamada R; Kodama T; Hikita H; Doi Y; Tamura S; Hagiwara H; Imai Y; Iio S; Tatsumi T; Takehara T
    PLoS One; 2020; 15(6):e0234811. PubMed ID: 32544182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.